|
US6203803B1
(en)
|
1994-12-14 |
2001-03-20 |
Societe L'oreal S.A. |
Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
|
|
CN1234029A
(zh)
*
|
1996-08-27 |
1999-11-03 |
盐野义制药株式会社 |
色烯－3－羚酸衍生物
|
|
US6077850A
(en)
*
|
1997-04-21 |
2000-06-20 |
G.D. Searle & Co. |
Substituted benzopyran analogs for the treatment of inflammation
|
|
US6034256A
(en)
|
1997-04-21 |
2000-03-07 |
G.D. Searle & Co. |
Substituted benzopyran derivatives for the treatment of inflammation
|
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
|
US6306819B1
(en)
*
|
1997-10-31 |
2001-10-23 |
Massachusetts Institute Of Technology |
Method for regulating size of vascularized normal tissue
|
|
KR20000001793A
(ko)
*
|
1998-06-13 |
2000-01-15 |
이경하 |
신규한 벤조피란 또는 티오벤조피란 유도체
|
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20020103141A1
(en)
*
|
1998-12-23 |
2002-08-01 |
Mckearn John P. |
Antiangiogenic combination therapy for the treatment of cancer
|
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
CO5261541A1
(es)
*
|
1999-05-14 |
2003-03-31 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de la migrana
|
|
CO5190664A1
(es)
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
|
|
WO2001034135A2
(en)
*
|
1999-11-11 |
2001-05-17 |
Eli Lilly And Company |
Oncolytic combinations for the treatment of cancer
|
|
WO2001034134A2
(en)
*
|
1999-11-11 |
2001-05-17 |
Eli Lilly And Company |
Oncolytic combinations for the treatment of cancer
|
|
WO2001034137A2
(en)
*
|
1999-11-11 |
2001-05-17 |
Eli Lilly And Company |
Oncolytic combinations for the treatment of cancer
|
|
WO2001034133A2
(en)
*
|
1999-11-11 |
2001-05-17 |
Eli Lilly And Company |
Oncolytic combinations for the treatment of cancer
|
|
KR100793668B1
(ko)
*
|
1999-12-08 |
2008-01-10 |
파마시아 코포레이션 |
강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
|
|
AP2002002582A0
(en)
|
1999-12-23 |
2002-09-30 |
Nitromed Inc |
Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
|
|
US6822102B2
(en)
*
|
2000-01-03 |
2004-11-23 |
Pharmacia Corporation |
Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2 mediated disorders
|
|
JP2004503601A
(ja)
*
|
2000-07-13 |
2004-02-05 |
ファルマシア・コーポレーション |
眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
|
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
|
KR20030027016A
(ko)
*
|
2000-08-09 |
2003-04-03 |
에프. 호프만-라 로슈 아게 |
항-염증제로서의 퀴놀린 유도체
|
|
FR2817749A1
(fr)
*
|
2000-12-13 |
2002-06-14 |
Aventis Pharma Sa |
Nouvelle utilisation des composes de la classe des chalcones
|
|
KR20080079341A
(ko)
*
|
2001-01-16 |
2008-08-29 |
아스트라제네카 아베 |
치료용 헤테로시클릭 화합물
|
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
|
WO2002062391A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
|
|
CA2435835A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
|
|
CZ20032691A3
(en)
|
2001-03-12 |
2004-04-14 |
Avanir Pharmaceuticals |
Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
|
|
US7012098B2
(en)
*
|
2001-03-23 |
2006-03-14 |
Pharmacia Corporation |
Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
|
|
PE20021017A1
(es)
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
|
PL367337A1
(pl)
*
|
2001-05-31 |
2005-02-21 |
Pharmacia Corporation |
Przenikająca przez skórę kompozycja selektywnego inhibitora cyklooksygenazy-2
|
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
|
US20030114418A1
(en)
*
|
2001-08-14 |
2003-06-19 |
Pharmacia Corporation |
Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
|
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
|
JP2005505586A
(ja)
*
|
2001-10-04 |
2005-02-24 |
ワイス |
５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
|
|
US20050043409A1
(en)
*
|
2001-10-25 |
2005-02-24 |
Chen Ying-Nan Pan |
Combinations comprising a selective cyclooxygenase-2 inhibitor
|
|
MXPA04006572A
(es)
*
|
2002-01-10 |
2005-11-04 |
Upjohn Co |
Terapia de combinacion antivirica.
|
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
|
DE60325956D1
(de)
*
|
2002-04-10 |
2009-03-12 |
Dongbu Hitek Co Ltd |
Benzopyranderivate, die mit sekundären aminen einschliesslich tetrazol substituiert sind, verfahren etzungen, die diese enthalten
|
|
EP1505962A2
(en)
*
|
2002-04-18 |
2005-02-16 |
Pharmacia Corporation |
Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
|
|
US20040034083A1
(en)
*
|
2002-04-18 |
2004-02-19 |
Stephenson Diane T. |
Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
|
|
JP2005535642A
(ja)
|
2002-06-28 |
2005-11-24 |
ニトロメッド インコーポレーティッド |
オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
|
|
JP2005535657A
(ja)
*
|
2002-07-02 |
2005-11-24 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−２選択阻害剤及び血栓溶解剤の血管閉塞イベントの治療又は予防への使用
|
|
CN101327325A
(zh)
|
2002-07-30 |
2008-12-24 |
奥默罗斯公司 |
眼科冲洗液及方法
|
|
US20040138296A1
(en)
*
|
2002-08-12 |
2004-07-15 |
Pharmacia Corporation |
Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
|
|
WO2004024655A2
(en)
|
2002-09-12 |
2004-03-25 |
Avanir Pharmaceuticals |
Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
|
|
TWI276631B
(en)
|
2002-09-12 |
2007-03-21 |
Avanir Pharmaceuticals |
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
|
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
|
AU2003303041B2
(en)
|
2002-12-13 |
2008-07-24 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
|
JP2006512367A
(ja)
*
|
2002-12-19 |
2006-04-13 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−２選択阻害剤又はシクロオキシゲナーゼ−２阻害剤を抗ウイルス剤と組み合わせて使用する、ヘルペス・ウイルス感染症の治療の方法及び組成物
|
|
AU2003300264A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
|
US7259266B2
(en)
|
2003-03-31 |
2007-08-21 |
Pharmacia Corporation |
Benzopyran compounds useful for treating inflammatory conditions
|
|
US20050148627A1
(en)
*
|
2003-03-31 |
2005-07-07 |
Jeffery Carter |
Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
|
|
WO2004093896A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
|
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
|
US20040220187A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
|
|
US20060135506A1
(en)
*
|
2003-04-22 |
2006-06-22 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
|
WO2004093816A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
|
|
WO2004093811A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
|
ES2275218T3
(es)
|
2003-05-07 |
2007-06-01 |
Osteologix A/S |
Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
|
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
|
US20050026919A1
(en)
*
|
2003-05-14 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
|
|
WO2004103283A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
|
WO2004110456A1
(en)
*
|
2003-05-27 |
2004-12-23 |
Pharmacia Corporation |
Fcompositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
|
|
WO2004105699A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
|
WO2005016243A2
(en)
*
|
2003-06-09 |
2005-02-24 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
|
US20050004224A1
(en)
*
|
2003-06-10 |
2005-01-06 |
Pharmacia Corporation |
Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
|
|
CA2528634A1
(en)
*
|
2003-06-24 |
2005-01-06 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea
|
|
US20050080083A1
(en)
*
|
2003-07-10 |
2005-04-14 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
|
|
US20050101597A1
(en)
*
|
2003-07-10 |
2005-05-12 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
|
|
WO2005016249A2
(en)
*
|
2003-07-11 |
2005-02-24 |
Pharmacia Corporation |
Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
|
|
WO2005018541A2
(en)
*
|
2003-07-11 |
2005-03-03 |
Pharmacia Corporation |
Cox-2 inhibitor and serotonin modulator for treating cns damage
|
|
US20050014729A1
(en)
*
|
2003-07-16 |
2005-01-20 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
|
US20050085478A1
(en)
*
|
2003-08-22 |
2005-04-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
|
WO2005018563A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
|
BRPI0413679A
(pt)
*
|
2003-08-22 |
2006-10-24 |
Pharmacia Corp |
formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia
|
|
US20050085479A1
(en)
*
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20050113409A1
(en)
*
|
2003-09-03 |
2005-05-26 |
Pharmacia Corporation |
Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
|
|
ITTO20030140U1
(it)
*
|
2003-09-16 |
2005-03-17 |
Interfila Srl |
Matita cosmetica
|
|
WO2005033093A1
(en)
|
2003-09-19 |
2005-04-14 |
Galileo Pharmaceuticals, Inc. |
7,8-bicycloalkyl-chroman derivatives
|
|
MXPA06003663A
(es)
*
|
2003-10-03 |
2006-06-05 |
Pharmacia Corp |
Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
|
|
CA2542277A1
(en)
*
|
2003-10-21 |
2005-05-12 |
Pharmacia Corporation |
Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
|
|
BRPI0415939A
(pt)
*
|
2003-11-12 |
2007-01-02 |
Pharmacia & Upjohn Co Llc |
composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
|
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
|
CA2563963A1
(en)
*
|
2004-04-28 |
2005-11-10 |
Pfizer Inc. |
3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
|
|
EP1778662A1
(en)
*
|
2004-07-23 |
2007-05-02 |
Warner-Lambert Company LLC |
Photoracemization of 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
|
|
WO2006011052A1
(en)
*
|
2004-07-23 |
2006-02-02 |
Pharmacia & Upjohn Company Llc |
Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
|
|
US7122700B2
(en)
*
|
2004-07-30 |
2006-10-17 |
Xerox Corporation |
Arylamine processes
|
|
MX2007005361A
(es)
*
|
2004-11-05 |
2008-01-11 |
Cephalon Inc |
Tratamientos para cancer.
|
|
US8436190B2
(en)
*
|
2005-01-14 |
2013-05-07 |
Cephalon, Inc. |
Bendamustine pharmaceutical compositions
|
|
CA2763671A1
(en)
|
2005-04-26 |
2006-11-02 |
Pfizer Inc. |
P-cadherin antibodies
|
|
WO2006121887A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
|
CA2608718A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Pfizer Limited |
1, 2, 4-triazole derivatives as vasopressin antagonists
|
|
NZ566774A
(en)
|
2005-09-07 |
2011-11-25 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
UY29892A1
(es)
*
|
2005-11-04 |
2007-06-29 |
Astrazeneca Ab |
Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
|
|
CA2673545A1
(en)
|
2006-12-22 |
2008-07-03 |
Recordati Ireland Limited |
Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
|
|
EP2114461A2
(en)
*
|
2007-01-19 |
2009-11-11 |
Mallinckrodt Inc. |
Diagnostic and therapeutic cyclooxygenase-2 binding ligands
|
|
US8906632B2
(en)
|
2007-03-23 |
2014-12-09 |
Korea University Research & Business Foundation |
Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
|
|
US20100034835A1
(en)
*
|
2007-03-23 |
2010-02-11 |
Korea University Industrial & Academic Collaboration Foundation |
Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma
|
|
AR072777A1
(es)
|
2008-03-26 |
2010-09-22 |
Cephalon Inc |
Formas solidas de clorhidrato de bendamustina
|
|
CA2735899A1
(en)
*
|
2008-09-25 |
2010-04-01 |
Cephalon, Inc. |
Liquid formulations of bendamustine
|
|
US8076366B2
(en)
*
|
2009-01-15 |
2011-12-13 |
Cephalon, Inc. |
Forms of bendamustine free base
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
WO2013058303A1
(ja)
|
2011-10-18 |
2013-04-25 |
ラクオリア創薬株式会社 |
医薬組成物
|
|
CN102757417B
(zh)
|
2012-06-18 |
2014-09-24 |
中国科学院广州生物医药与健康研究院 |
氘代苯并吡喃类化合物及其应用
|
|
AU2013201465B2
(en)
|
2012-10-24 |
2016-03-03 |
Rayner Intraocular Lenses Limited |
Stable preservative-free mydriatic and anti-inflammatory solutions for injection
|
|
CN103044477B
(zh)
*
|
2012-12-07 |
2015-08-05 |
中国科学院广州生物医药与健康研究院 |
三甲基硅取代苯并吡喃类化合物及其应用
|
|
CN103012350B
(zh)
*
|
2012-12-07 |
2015-02-04 |
中国科学院广州生物医药与健康研究院 |
苯并吡喃类手性化合物的合成方法
|
|
TWI646091B
(zh)
|
2012-12-28 |
2019-01-01 |
日商衛斯克慧特股份有限公司 |
鹽類及晶形
|
|
EP2979695B1
(en)
*
|
2013-03-29 |
2018-08-01 |
AskAt Inc. |
Therapeutic agent for ocular disease
|
|
WO2015109014A1
(en)
*
|
2014-01-14 |
2015-07-23 |
Euclises Pharmaceuticals, Inc. |
No-releasing nonoate(oxygen-bound)chromene conjugates
|
|
CN104860914B
(zh)
*
|
2014-02-26 |
2018-09-14 |
中国科学院广州生物医药与健康研究院 |
五氟化硫取代苯并吡喃类化合物及其应用
|
|
TWI705812B
(zh)
|
2014-12-01 |
2020-10-01 |
奥默羅斯公司 |
用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
|
|
WO2016149126A1
(en)
|
2015-03-13 |
2016-09-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ltb4 inhibition to prevent and treat human lymphedema
|
|
EP3400218A4
(en)
|
2016-01-08 |
2019-09-18 |
Euclises Pharmaceuticals, Inc. |
COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
|
|
US11583516B2
(en)
|
2016-09-07 |
2023-02-21 |
Trustees Of Tufts College |
Dash inhibitors, and uses related thereto
|
|
KR102533957B1
(ko)
|
2019-01-22 |
2023-05-17 |
에스크엣 인크. |
치환된 2h-크로멘-3-카르복실산의 상이한 용해도-유도된 비대칭 변환 방법
|
|
US20200237715A1
(en)
*
|
2019-04-05 |
2020-07-30 |
John James Vrbanac, JR. |
COX-2 Inhibitors for the Treatment of Ocular Disease
|
|
CN111647003B
(zh)
*
|
2020-06-08 |
2022-06-21 |
中国科学院昆明植物研究所 |
三环氧六氢色酮a及其药物组合物和其应用
|
|
CN114671827B
(zh)
*
|
2020-12-24 |
2024-09-20 |
杭州百新生物医药科技有限公司 |
邻苯甲酰磺酰亚胺类衍生物及其应用
|
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
|
|
CN117800941A
(zh)
*
|
2022-12-27 |
2024-04-02 |
思路迪生物医药(上海)有限公司 |
一种苯并吡喃类化合物的晶型及其制备方法
|